Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kaletra, Epivir, Sustiva, and Tenofovir DF in HIV-1
NCT00038220Phase 2Completed
- Sponsor
- Abbott Laboratories
- Start
- Jul 2000
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lopinavir + ritonavir in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Abbott Laboratories. Primary endpoint: Proportion of subjects demonstrating complete suppression of viral replication at 144 weeks. Started Jul 2000; status: completed.
02
Drugs
lopinavir + ritonavir
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT00038220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00038220.